European speciality pharmaceutical company with a portfolio of urology products
SEP acquired and licensed several products for the European specialty urology and urogynaecology market. SEP sold a number of brands including Mitem®/Mitocin for bladder cancer and Regurin® for overactive bladder through its own sales force at the time of its acquisition.
CEO Patrick Banks
Advent founded SEP in 2006. SEP was acquired by Juno/ Aspire Pharmaceuticals in 2016.
SEP, the Pan-European Specialty Urology Company, acquires Mitem
Press Release. Speciality European Pharma Limited (SEP), the pan European urology focused specialty pharmaceutical company, is pleased to announce its acquisition of the product Mitem® from Curasan AG. Mitem…Read More
SEP Signs REGURIN® Deal
Press Release. LONDON, June 18 /PRNewswire Speciality Urology Company Gains Exclusive UK Distribution Rights Speciality European Pharma Limited (SEP), the UK based, urology focused, specialty pharmaceutical company, is…Read More
SEP, the specialty urology company, closes a $15M series B financing
Press Release. Speciality European Pharma Limited (SEP), the UK based, urology focused, specialty pharmaceutical company, is pleased to announce the successful completion of a €15M series B financing led…Read More